近年来，嵌合抗原受体 T 细胞 (CAR-T) 疗法已成为治疗难治性和复发性造血系统恶性肿瘤的一种高效治疗方式。此外，用于癌症免疫治疗的CAR技术已从CAR-T扩展到CAR-自然杀伤细胞（CAR-NK）、CAR-细胞因子诱导杀伤细胞（CAR-CIK）和CAR-巨噬细胞（CAR-MΦ）治疗。然而，离体生成自体CAR产品的高成本和复杂的制造工艺阻碍了更广泛的应用。迫切需要开发一种高效且经济的范式转变，以探索新的采购策略和工程方法，以生成 CAR 工程免疫细胞，造福癌症患者。目前，研究人员正在积极研究各种策略来优化这些有效免疫治疗剂的制备和采购。本文总结了最新的研究进展。提供了对 CAR 工程免疫细胞制造的未来的展望，并重点讨论了工程方法以及用于其开发的多种来源。© 2023 作者。 《先进科学》由 Wiley-VCH GmbH 出版。

Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a highly efficacious treatment modality for refractory and relapsed hematopoietic malignancies in recent years. Furthermore, CAR technologies for cancer immunotherapy have expanded from CAR-T to CAR-natural killer cell (CAR-NK), CAR-cytokine-induced killer cell (CAR-CIK), and CAR-macrophage (CAR-MΦ) therapy. Nevertheless, the high cost and complex manufacturing processes of ex vivo generation of autologous CAR products have hampered broader application. There is an urgent need to develop an efficient and economical paradigm shift for exploring new sourcing strategies and engineering approaches toward generating CAR-engineered immune cells to benefit cancer patients. Currently, researchers are actively investigating various strategies to optimize the preparation and sourcing of these potent immunotherapeutic agents. In this work, the latest research progress is summarized. Perspectives on the future of CAR-engineered immune cell manufacturing are provided, and the engineering approaches, and diverse sources used for their development are focused upon.© 2023 The Authors. Advanced Science published by Wiley-VCH GmbH.